Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

N-905

Supelco

Nordiazepam solution

1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C15H11ClN2O
Número CAS:
Peso molecular:
270.71
Número CE:
Código UNSPSC:
41116107
NACRES:
NA.24

grau

certified reference material

Nível de qualidade

Formulário

liquid

embalagem

ampule of 1 mL

fabricante/nome comercial

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

concentração

1 mg/mL in methanol

técnica(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicação(ões)

clinical testing

Formato

single component solution

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

Clc1ccc2NC(=O)CN=C(c3ccccc3)c2c1

InChI

1S/C15H11ClN2O/c16-11-6-7-13-12(8-11)15(17-9-14(19)18-13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19)

chave InChI

AKPLHCDWDRPJGD-UHFFFAOYSA-N

Descrição geral

Nordiazepam is a benzodiazepine prescribed for treatment of anxiety and panic attacks. This analytical reference standard is suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, or urine drug testing applications. Nordiazepam is also a primary urinary metabolite of benzodiazepines diazepam and chlrodiazepoxide.

Produtos recomendados

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

Informações legais

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

produto relacionado

Nº do produto
Descrição
Preços

Palavra indicadora

Danger

Classificações de perigo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órgãos-alvo

Eyes,Central nervous system

Código de classe de armazenamento

3 - Flammable liquids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

49.5 °F - closed cup

Ponto de fulgor (°C)

9.7 °C - closed cup


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Craig Lehmann et al.
Journal of clinical pharmacology, 48(4), 436-444 (2008-02-02)
A diazepam 10-mg autoinjector was evaluated in bioequivalence and dose proportionality studies; both involved 24 young, healthy subjects and used randomized, open-label, 2-treatment, 2-period crossover designs with a 3-week washout period between treatments. The bioequivalence study compared a single diazepam
Shanlin Fu et al.
Journal of analytical toxicology, 34(5), 243-251 (2010-06-10)
beta-Glucuronidase is an enzyme often employed to de-conjugate beta-glucuronides during urinary drug testing for benzodiazepines. It is commonly accepted that use of beta-glucuronidase is a preferred method of hydrolysis over acid-catalyzed hydrolysis, which is known to induce benzodiazepine degradation and
David A Fishbain et al.
Pain medicine (Malden, Mass.), 10(3), 565-572 (2008-11-11)
The objectives of this medicolegal case report are the following: 1) to present details of a chronic pain patient (CPP) who was placed on chronic opioid analgesic therapy (COAT), and subsequently overdosed on multiple drugs, some of which were not
Ali Acikgöz et al.
Toxicology and applied pharmacology, 234(2), 179-191 (2008-11-06)
Drug biotransformation is one of the most important parameters of preclinical screening tests for the registration of new drug candidates. Conventional existing tests rely on nonhuman models which deliver an incomplete metabolic profile of drugs due to the lack of
Joris C Verster et al.
Sleep medicine reviews, 17(2), 153-159 (2012-08-14)
The use of benzodiazepine receptor agonists can significantly impair driving performance. The aim of this review was to determine if there is a relation between blood concentrations of these drugs and the degree of driving impairment. A literature search was

Global Trade Item Number

SKUGTIN
N-905-1ML4061834092568

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica